Berkshire Hathaway reveals $4.3 billion stake in Alphabet, cuts Apple
Investing.com - Stifel has reduced its price target on Abeona Therapeutics (NASDAQ:ABEO) to $19.00 from $20.00 while maintaining a Buy rating on the stock. Currently trading at $5.07 with a market cap of $260.24 million, ABEO has a strong Buy consensus among analysts, with targets ranging from $14.00 to $27.50. InvestingPro data shows the stock’s RSI suggests it’s in oversold territory following its recent 25% six-month decline.
The price target adjustment follows Abeona’s temporary pause in patient biopsy collection, which has delayed the commercial launch of Zevaskyn by approximately three months. The pause was implemented due to a performance issue with an FDA-mandated sterility assay that produced a false positive on patient-derived drug product.
Patient biopsy scheduling resumed earlier this month, but Stifel has decreased its fourth-quarter 2025 revenue estimate to $8 million, reflecting expectations for only three patients to be treated. The firm cited uncertainty around revenue recognition timing, particularly given the mid-December manufacturing shutdown for annual quality control purposes. Despite these challenges, InvestingPro data reveals Abeona maintains a healthy current ratio of 6.73, indicating strong liquidity with assets well exceeding short-term obligations.
Despite the near-term setback, Stifel expressed increased confidence in its fiscal year 2026 and beyond Zevaskyn estimates, based on management’s commentary regarding demand trends. The company has received 12 patient start forms and identified approximately 30 patients from activated qualified treatment centers, with referrals increasing. InvestingPro analysis indicates net income is expected to grow this year, with EPS forecast at $0.12 for FY2025 and a current P/E ratio of 5.11, suggesting potential value despite the company trading slightly above its Fair Value.
Abeona has also made progress on the reimbursement front, securing a permanent J-code, coverage for approximately 80% of commercial lives, and inclusion in all state Medicaid programs, which Stifel believes will support the company’s path to sustainable profitability. Another positive indicator from InvestingPro data shows Abeona holds more cash than debt on its balance sheet, potentially providing financial flexibility during this critical commercialization phase.
In other recent news, Abeona Therapeutics reported a significant improvement in its third-quarter 2025 earnings. The company exceeded analyst expectations with an earnings per share (EPS) of -$0.10, compared to the projected -$0.27. This represents a positive surprise of 62.96%. The favorable results were attributed to strategic cost management and promising product developments. Analysts have noted these factors as contributing to the company’s improved financial performance. Abeona Therapeutics’ earnings report was well-received, highlighting the company’s ability to manage costs effectively. These recent developments are crucial for investors monitoring the company’s financial health and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.